1,25-dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2644-2649

  Hershberger, Pamela A ^a,c   Modzelewski, Ruth A ^a   Shurin, Zoya R ^a   Rueger, Robert M ^a   Trump, Donald L ^a,b   Johnson, Candace S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PROTEIN P21;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; DEPHOSPHORYLATION; DOWN REGULATION; DRUG EFFECT; GROWTH INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DEXAMETHASONE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; G0 PHASE; G1 PHASE; MICE; MICE, INBRED C3H; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033152196     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Studzinski, G. P., and Moore, D. C. Sunlight - can it prevent as well as cause cancer? Cancer Res., 55: 4014-4022, 1995.
2. Gross, C., Peehl, D. M., and Feldman, D. Vitamin D and prostate cancer. In: D. Feldman, F. H. Glorieux, and J. W. Pike (eds.), Vitamin D, pp. 1125-1139. San Diego: Academic Press, 1997.
3. Evans, S. R. T., Nolla, J., Hanfelt, J., Shabahang, M., Nauta, R. J., and Shchepotin, I. B. Vitamin D receptor expression as a predictive marker of biological behavior in human coloreclal cancer. Clin. Cancer Res., 4: 1591-1595, 1998.
4. 3. Proc. Natl. Acad. Sci. USA, 78: 4990-4995, 1981.
5. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 10: 142-153, 1996.
6. Jiang, H., Lin, J., Su, Z-Z., Collart, F. R., Huberman, E., and Fisher, P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, Waf1/Cip1, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994.
7. Getzenberg, R. H., Light, B. W., Lapco, P. E., Konety, B. R., Nangia, A. K., Acierno, J. S., Dhir, R., Shurin, Z., Day, R. S., Trump, D. L, and Johnson, C. S. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the dunning rat prostate model system. Urology, 50: 999-1006, 1997.
8. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J. Steroid Biochem., 24: 373-376, 1986.
9. Colston, K. W., Chander, S. K., Mackay, A. G., and Coombes, R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochemical Pharm., 44: 693-702, 1992.
10. 3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res., 53: 3712-3718, 1993.
11. Kawa, S., Nikaido, T., Aoki, Y., Zhai, Y., Kumagai, T., Furihata, K., Fujii, S., and Kiyosowa, K. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer, 76: 884-889, 1997.
12. 3. Cancer Res., 47: 21-25, 1987.
13. 3 analog in a squamous cell carcinoma model system. Mol. Cell. Differ., 3: 31-50, 1995.
14. Van Leeuwen, J. P. T. M., and Pols, A. P. Vitamin D: anticancer and differentiation. In: D. Feldman, F. H. Glorieux, and J. W. Pike (eds.), Vitamin D, pp. 1089-1105. San Diego: Academic Press, 1997.
15. 3 are mediated exclusively through the genomic signaling pathway. Endocrinology, 137: 1554-1561, 1996.
16. 3 in the human prostatic carcinoma cell line ALVA-31. J. Steroid Biochem. Mol. Biol., 58: 277-288, 1996.
17. Darwish, H. M., and DeLuca, H. F. Recent advances in the molecular biology of vitamin D action. Prog. Nucleic Acid Res. Mol. Biol., 53: 321-344, 1996.
18. Light, B. W., Yu, W-D., McElwain, M. C., Russell, D. M., Tramp, D. L., and Johnson, C. S. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res., 57: 3759-3764, 1997.
19. 3-mediated antitumor activity with dexamethasone. J. Natl. Cancer Inst., 90: 134-141, 1998.
20. 3 in HL60 cells. Cancer Res., 56: 264-267, 1996.
21. kip1, and E-cadherin. J. Mol. Endocrinol., 19: 15-27, 1997.
22. 1 accumulation. Endocrinology, 139: 1197-1207, 1998.
23. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
24. Steinman, R. A., Hoffman. B., Iro, A., Guillouf, C., Liebermann, D. A., and El-Houseini, M. E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene, 9: 3389-3396, 1994.
25. 3-treated HL60 cells. Cancer Res., 57: 2851-2855, 1997.
26. Suit, H. D., Sedlacek, R. S., Silver, G., and Dosoretz, D. Pentobarbital anesthesia and the response of tumor and normal tissue in the C3Hf/Sed mouse to radiation. Radiat. Res., 104: 47-65, 1985.
27. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
28. 3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 58: 367-376, 1996.
29. 3 derivatives and breast-tumor cell growth; effect on intracellular calcium and apoptosis. Int. J. Cancer, 61: 806-811, 1995.
30. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose)polymerase. Cell, 81: 801-809, 1995.
31. Santiso-Mere, D., Sone, T., Milliard, G. M., IV, Pike, J. W., and McDonnell, D. P. Positive regulation of the vitamin D receptor by its cognate ligand in heterologous expression systems. Mol. Endocrinol., 7: 833-839, 1993.
32. Eastham, J. A., Hall, S. J., Sehgal, I., Wang, J., Timme, T. L., Yang, G., Connell-Crowley, L., Elledge, S. J., Zhang, W-W., Harper, J-W., and Thompson, T. C. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res., 55: 5151-5155, 1995.
33. waf1. Cancer Res., 55: 4536-4539, 1995.
34. Barboule, N., Chadebech, P., Baldin, V., Vidal, S., and Vallette, A. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene, 15: 2867-2875, 1997.
35. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
36. Cip1/Waf1 correlates with terminal differentiation of squamous cell carcinoma lines. Cell Growth Differ., 9: 619-627, 1998.
37. Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science (Washington DC), 280: 1069-1072, 1998.
38. (Kip1) mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. Mol. Cell, 1: 553-563, 1998.
39. Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G. H., Ishizaka, Y., Liu, J., Haqqi, T., Nishiyama, A., Villeponteau, B., Cowell, J. K., and Barna, B. P. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J., 12: 801-811, 1998.
40. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
41. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., and O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997.
42. 3-mediated effects. J. Immunol., 160: 209-218, 1998.
43. 3 receptor. J. Biol. Chem., 273: 10338-10348, 1998.
44. Cayrol, C., and Ducommun, B. Interaction with cyclin-dependent kinases and PCNA modulates proteosome-dependent degradation of p21. Oncogene, 17: 2437-2444, 1998.